Company intelligence / Profile preview
PAION AG
Aachen, North Rhine-Westphalia, Germanypaion.com ↗
- Ownership
- Public · PA8
- Development stage
- Commercial
01
Overview
PAION successfully developed Remimazolam (brand name Byfavo), an ultra-short-acting benzodiazepine sedative/anesthetic that received market approval in 2020 in Japan, followed by the US and China.
- Therapeutic areas
- OtherPsychiatryNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
La Jolla (licensing agreement for angiotensin II and eravacycline in Europe)
04
Financials
- Market cap
- $723.4M
- Total revenue
- $1.5B
Beyond the preview
Go deeper on PAION AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAION AG.